Keyword Search Results for "antiplatelet"

Becker, R. C., Bovill, E. G., Corrao, J. M., Ball, S. P., Ault, K., Mann, K., Tracy, R. P. Platelet Activation Determined by Flow Cytometry Persists Despite Antithrombotic Therapy in Patients with Unstable Angina and Non-Q-Wave Myocardial Infarction Journal of thrombosis and thrombolysis. 1994;1(1):95-100. Abstract

Cannon CP, McCabe CH, Borzak S, Henry TD, Tischler MD, Mueller HS, Feldman R, Palmeri ST, Ault K, Hamilton SA, Rothman JM, Novotny WF, Braunwald E. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: results of the TIMI 12 trial. Circulation. 1998;97:340-9. Abstract

Cannon, C. P., Weintraub, W. S., Demopoulos, L. A., Robertson, D. H., Gormley, G. J., Braunwald, E. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction Am J Cardiol. 1998;82(6):731-6. Abstract

Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AA, Menown I, Rupprecht HJ, Van der Wieken R, Ducas J, Scherer J, Anderson K, Van de Werf F, Braunwald E. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation. 1999;99:2720-32. Abstract

Ault, K. A., Cannon, C. P., Mitchell, J., McCahan, J., Tracy, R. P., Novotny, W. F., Reimann, J. D., Braunwald, E. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction J Am Coll Cardiol. 1999;33(3):634-9. Abstract

Weintraub, W. S., Culler, S. D., Kosinski, A., Becker, E. R., Mahoney, E., Burnette, J., Spertus, J. A., Feeny, D., Cohen, D. J., Krumholz, H., Ellis, S. G., Demopoulos, L., Robertson, D., Boccuzzi, S. J., Barr, E., Cannon, C. P. Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban]] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trial Am J Cardiol. 1999;83(3):317-22. Abstract

Antman, E. M., Gibson, C. M., de Lemos, J. A., Giugliano, R. P., McCabe, C. H., Coussement, P., Menown, I., Nienaber, C. A., Rehders, T. C., Frey, M. J., Van der Wieken, R., Andresen, D., Scherer, J., Anderson, K., Van de Werf, F., Braunwald, E. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators Eur Heart J. 2000;21(23):1944-53. Abstract

Cannon CP, McCabe CH, Wilcox RG, Langer A, Caspi A, Berink P, Lopez-Sendon J, Toman J, Charlesworth A, Anders RJ, Alexander JC, Skene A, Braunwald E. Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation. 2000;102:149-56. Abstract

Cannon, C. P. Learning from the recently completed oral glycoprotein IIb/IIIa receptor antagonist trials Clin Cardiol. 2000;23 Suppl 6(NA):VI-14-7. Abstract

Cannon, C. P. Bridging the gap with new strategies in acute ST elevation myocardial infarction: bolus thrombolysis, glycoprotein IIb/IIIa inhibitors, combination therapy, percutaneous coronary intervention, and "facilitated" PCI J Thromb Thrombolysis. 2000;9(3):235-41. Abstract

Giugliano RP, McCabe CH, Sequeira RF, Frey MJ, Henry TD, Piana RN, Tamby JF, Jensen BK, Nicolas SB, Jennings LK, Wise RJ, Braunwald E. First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials. Am Heart J. 2000;140:81-93. Abstract

Holmes, M. B., Sobel, B. E., Cannon, C. P., Schneider, D. J. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction Am J Cardiol. 2000;85(4):491-3, A10. Abstract

de Lemos, J. A., Antman, E. M., Gibson, C. M., McCabe, C. H., Giugliano, R. P., Murphy, S. A., Coulter, S. A., Anderson, K., Scherer, J., Frey, M. J., Van Der Wieken, R., Van De Werf, F., Braunwald, E. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial Circulation. 2000;101(3):239-43. Abstract

O'Connor, F. F., Shields, D. C., Fitzgerald, A., Cannon, C. P., Braunwald, E., Fitzgerald, D. J. Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes Blood. 2001;98(12):3256-60. Abstract

Roe, Matthew T., Giugliano, Robert P., Harrington, Robert A., Gibson, C. Michael, Strony, John, Kitt, Michael M., Califf, Robert M., Braunwald, Eugene Combination reperfusion therapy with eptifibatide and tenecteplase for acute myocardial infarction. Design and methodology of the INTEGRITI (Integrilin and Tenecteplase for Acute Myocardial Infarction) trial HeartDrug. 2001;1(1):13-May.

Santopinto, J., Gurfinkel, E. P., Torres, V., Marcos, E., Bozovich, G. E., Mautner, B., McCabe, C. H., Antman, E. M. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin Am Heart J. 2001;141(4):566-72. Abstract

de Lemos, J. A., Gibson, C. M., Antman, E. M., Murphy, S. A., Morrow, D. A., Schuhwerk, K. C., Schweiger, M., Coussement, P., Van de Werf, F., Braunwald, E. Abciximab and early adjunctive percutaneous coronary intervention are associated with improved ST-segment resolution after thrombolysis: Observations from the TIMI 14 Trial Am Heart J. 2001;141(4):592-8. Abstract

Brassard, J. A., Curtis, B. R., Cooper, R. A., Ferguson, J., Komocsar, W., Ehardt, M., Kupfer, S., Maurath, C., Swabb, E., Cannon, C. P., Aster, R. H. Acute thrombocytopenia in patients treated with the oral glycoprotein IIb/IIIa inhibitors xemilofiban and orbofiban: evidence for an immune etiology Thromb Haemost. 2002;88(6):892-7. Abstract

Brener, S. J., Murphy, S. A., Gibson, C. M., DiBattiste, P. M., Demopoulos, L. A., Cannon, C. P. Efficacy and safety of multivessel percutaneous revascularization and tirofiban therapy in patients with acute coronary syndromes Am J Cardiol. 2002;90(6):631-3.

Kenny, D., Muckian, C., Fitzgerald, D. J., Cannon, C. P., Shields, D. C. Platelet glycoprotein Ib alpha receptor polymorphisms and recurrent ischaemic events in acute coronary syndrome patients J Thromb Thrombolysis. 2002;13(1):13-9. Abstract

Morrow, D. A., Antman, E. M., Snapinn, S. M., McCabe, C. H., Theroux, P., Braunwald, E. An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS Eur Heart J. 2002;23(3):223-9. Abstract

de Lemos, J. A., Morrow, D. A., Gibson, C. M., Murphy, S. A., Sabatine, M. S., Rifai, N., McCabe, C. H., Antman, E. M., Cannon, C. P., Braunwald, E. The prognostic value of serum myoglobin in patients with non-ST-segment elevation acute coronary syndromes. Results from the TIMI 11B and TACTICS-TIMI 18 studies J Am Coll Cardiol. 2002;40(2):238-44. Abstract

Cannon, C. P. Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: insights from the TACTICS TIMI-18 trial J Am Coll Cardiol. 2003;41(4 Suppl S):43S-48S. Abstract

Giugliano RP, Roe MT, Harrington RA, Gibson CM, Zeymer U, Van de Werf F, Baran KW, Hobbach HP, Woodlief LH, Hannan KL, Greenberg S, Miller J, Kitt MM, Strony J, McCabe CH, Braunwald E, Califf RM. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. J Am Coll Cardiol. 2003;41:1251-60.

Januzzi, J. L., Jr., Sabatine, M. S., Wan, Y., Servoss, S. J., DiBattiste, P. M., Jang, Ik, Theroux, P. Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy Am J Cardiol. 2003;91(4):457-61.

Serrano, C. V., Jr., Nicolau, J. C., Venturinelli, M., Baracioli, L. M., Anders, R. J., Cannon, C. P., Ramires, J. A. Role of oral blockade of platelet glycoprotein IIb/IIIa on neutrophil activation in patients with acute coronary syndromes Cardiovasc Drugs Ther. 2003;17(2):129-32. Abstract

Gibson, C. M., Jennings, L. K., Murphy, S. A., Lorenz, D. P., Giugliano, R. P., Harrington, R. A., Cholera, S., Krishnan, R., Califf, R. M., Braunwald, E. Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy Circulation. 2004;110(6):679-84.

Gibson, C. M., Singh, K. P., Murphy, S. A., DiBattiste, P. M., Demopoulos, L. A., Cannon, C. P., Braunwald, E. Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy) Am J Cardiol. 2004;94(4):492-4. Abstract

Karha, J., Gibson, C. M., Murphy, S. A., Dibattiste, P. M., Cannon, C. P. Safety of stress testing during the evolution of unstable angina pectoris or non-ST-elevation myocardial infarction Am J Cardiol. 2004;94(12):1537-9. Abstract

Mega, J. L., Morrow, D. A., De Lemos, J. A., Sabatine, M. S., Murphy, S. A., Rifai, N., Gibson, C. M., Antman, E. M., Braunwald, E. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy J Am Coll Cardiol. 2004;44(2):335-9. Abstract

Morrow, D. A., Sabatine, M. S., Antman, E. M., Cannon, C. P., Braunwald, E., Theroux, P. Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS) Am J Cardiol. 2004;94(6):774-6. Abstract

Roe, M. T., Green, C. L., Giugliano, R. P., Gibson, C. M., Baran, K., Greenberg, M., Palmeri, S. T., Crater, S., Trollinger, K., Hannan, K., Harrington, R. A., Krucoff, M. W. Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction J Am Coll Cardiol. 2004;43(4):549-56.

Sabatine, M. S., Morrow, D. A., Giugliano, R. P., Murphy, S. A., Demopoulos, L. A., DiBattiste, P. M., Weintraub, W. S., McCabe, C. H., Antman, E. M., Cannon, C. P., Braunwald, E. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction - A Comparison of the Thrombolysis in Myocardial Infarction (TIMI) IIIB Trial and the Treat angina with Aggrastat and determine Cost of Therapy with Invasive or Conservative Strategy (TACTICS)-TIMI 18 Trial Circulation. 2004;109(7):874-880. Abstract

Sadanandan, S., Cannon, C. P., Chekuri, K., Murphy, S. A., Dibattiste, P. M., Morrow, D. A., de Lemos, J. A., Braunwald, E., Gibson, C. M. Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction J Am Coll Cardiol. 2004;44(3):564-8. Abstract

ADVANCE MI Investigators Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial Am Heart J. 2005;150(1):116-22.

Giugliano, R. P., Newby, L. K., Harrington, R. A., Gibson, C. M., Van de Werf, F., Armstrong, P., Montalescot, G., Gilbert, J., Strony, J. T., Califf, R. M., Braunwald, E. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale Am Heart J. 2005;149(6):994-1002. Abstract

Kirtane, A. J., Leder, D. M., Waikar, S. S., Chertow, G. M., Ray, K. K., Pinto, D. S., Karmpaliotis, D., Burger, A. J., Murphy, S. A., Cannon, C. P., Braunwald, E., Gibson, C. M. Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates J Am Coll Cardiol. 2005;45(11):1781-6. Abstract

Steinberg, B. A., Braganza, A. J., Eminowicz, G., Dibattiste, P. M., Flaker, G. C., Murphy, S. A., Cannon, C. P. Are statins being underdosed in clinical practice? Data from TACTICS-TIMI 18 Crit Pathw Cardiol. 2005;4(4):169-73. Abstract

Wiviott, S. D., Antman, E. M., Winters, K. J., Weerakkody, G., Murphy, S. A., Behounek, B. D., Carney, R. J., Lazzam, C., McKay, R. G., McCabe, C. H., Braunwald, E. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial Circulation. 2005;111(25):3366-73.

Bhadriraju, S., Ray, K. K., DeFranco, A. C., Barber, K., Bhadriraju, P., Murphy, S. A., Morrow, D. A., McCabe, C. H., Gibson, C. M., Cannon, C. P., Braunwald, E. Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial Am J Cardiol. 2006;97(11):1573-7. Abstract

Cannon, C. P., McLean, D. S. Critical pathways using platelet testing to potentially optimize the use of oral antiplatelet therapy Am J Cardiol. 2006;98(10A):33N-38N. Abstract

Gibson, C. M., Kirtane, A. J., Morrow, D. A., Palabrica, T. M., Murphy, S. A., Stone, P. H., Scirica, B. M., Jennings, L. K., Herrmann, H. C., Cohen, D. J., McCabe, C. H., Braunwald, E. Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30) Am Heart J. 2006;152(4):756-61.

Gibson, C. M., Kirtane, A. J., Murphy, S. A., Rohrbeck, S., Menon, V., Lins, J., Kazziha, S., Rokos, I., Shammas, N. W., Palabrica, T. M., Fish, P., McCabe, C. H., Braunwald, E. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial Am Heart J. 2006;152(4):668-75. Abstract

Gibson, C. M., Ly, H. Q., Murphy, S. A., Ciaglo, L. N., Southard, M. C., Stein, E. B., Buros, J. L., Sabatine, M. S., Cannon, C. P. Usefulness of clopidogrel in abolishing the increased risk of reinfarction associated with higher platelet counts in patients with ST-elevation myocardial infarction (results from CLARITY-TIMI 28) Am J Cardiol. 2006;98(6):761-3.

Gibson, C. M., Morrow, D. A., Murphy, S. A., Palabrica, T. M., Jennings, L. K., Stone, P. H., Lui, H. H., Bulle, T., Lakkis, N., Kovach, R., Cohen, D. J., Fish, P., McCabe, C. H., Braunwald, E. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial J Am Coll Cardiol. 2006;47(12):2364-73.

Kirtane, A. J., Piazza, G., Murphy, S. A., Budiu, D., Morrow, D. A., Cohen, D. J., Peterson, E., Lakkis, N., Herrmann, H. C., Palabrica, T. M., Gibson, C. M. Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial J Am Coll Cardiol. 2006;47(12):2374-9.

Scirica, B. M., Cannon, C. P., Cooper, R., Aster, R. H., Brassard, J., McCabe, C. H., Charlesworth, A., Skene, A. M., Braunwald, E. Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial J Thromb Thrombolysis. 2006;22(2):95-102. Abstract

Scirica, B. M., Sabatine, M. S., Morrow, D. A., Gibson, C. M., Murphy, S. A., Wiviott, S. D., Giugliano, R. P., McCabe, C. H., Cannon, C. P., Braunwald, E. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST-segment elevation myocardial infarction: the ECG CLARITY-TIMI 28 Study J Am Coll Cardiol. 2006;48(1):37-42.

Wiviott, S. D., Antman, E. M., Gibson, C. M., Montalescot, G., Riesmeyer, J., Weerakkody, G., Winters, K. J., Warmke, J. W., McCabe, C. H., Braunwald, E. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) Am Heart J. 2006;152(4):627-35. Abstract

Brandt, J. T., Payne, C. D., Wiviott, S. D., Weerakkody, G., Farid, N. A., Small, D. S., Jakubowski, J. A., Naganuma, H., Winters, K. J. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation Am Heart J. 2007;153(1):66 e9-16. Abstract

Cannon, C. P. Clopidogrel: who, when, and how? Rev Cardiovasc Med. 2007;8 Suppl 3(NA):S27-34. Abstract

Gibson, C. M., Buros, J., Ciaglo, L. N., Southard, M. C., Takao, S., Harrigan, C., Filopei, J., Lew, M., Marble, S. J., Murphy, S. A., Cohen, M. G. Impact of iodinated contrast injections on percent diameter coronary arterial stenosis and implications for trials of intracoronary pharmacotherapies in patients with ST-elevation myocardial infarction Am J Cardiol. 2007;100(1):13-7. Abstract

McLean, D. S., Sabatine, M. S., Guo, W., McCabe, C. H., Cannon, C. P. Benefits and risks of clopidogrel pretreatment before coronary artery bypass grafting in patients with ST-elevation myocardial infarction treated with fibrinolytics in CLARITY-TIMI 28 J Thromb Thrombolysis. 2007;24(2):85-91.

Storey, R. F., Husted, S., Harrington, R. A., Heptinstall, S., Wilcox, R. G., Peters, G., Wickens, M., Emanuelsson, H., Gurbel, P., Grande, P., Cannon, C. P. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes J Am Coll Cardiol. 2007;50(19):1852-6. Abstract

Verheugt, F. W., Montalescot, G., Sabatine, M. S., Soulat, L., Lambert, Y., Lapostolle, F., Adgey, J., Cannon, C. P. Prehospital fibrinolysis with dual antiplatelet therapy in ST-elevation acute myocardial infarction: a substudy of the randomized double blind CLARITY-TIMI 28 trial J Thromb Thrombolysis. 2007;23(3):173-9.

Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F. J., Ardissino, D., De Servi, S., Murphy, S. A., Riesmeyer, J., Weerakkody, G., Gibson, C. M., Antman, E. M. Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med. 2007;357(20):2001-15. Abstract

Wiviott, S. D., Trenk, D., Frelinger, A. L., O'Donoghue, M., Neumann, F. J., Michelson, A. D., Angiolillo, D. J., Hod, H., Montalescot, G., Miller, D. L., Jakubowski, J. A., Cairns, R., Murphy, S. A., McCabe, C. H., Antman, E. M., Braunwald, E. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial Circulation. 2007;116(25):2923-32. Abstract

Antman, E. M., Wiviott, S. D., Murphy, S. A., Voitk, J., Hasin, Y., Widimsky, P., Chandna, H., Macias, W., McCabe, C. H., Braunwald, E. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis J Am Coll Cardiol. 2008;51(21):2028-33. Abstract

Braunwald, E., Angiolillo, D., Bates, E., Berger, P. B., Bhatt, D., Cannon, C. P., Furman, M. I., Gurbel, P., Michelson, A. D., Peterson, E., Wiviott, S. Antiplatelet therapy and platelet function testing Clin Cardiol. 2008;31(3 Suppl 1):I36.

Braunwald, E., Angiolillo, D., Bates, E., Berger, P. B., Bhatt, D., Cannon, C. P., Furman, M. I., Gurbel, P., Michelson, A. D., Peterson, E., Wiviott, S. Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes Clin Cardiol. 2008;31(3 Suppl 1):I2-9. Abstract

Braunwald, E., Angiolillo, D., Bates, E., Berger, P. B., Bhatt, D., Cannon, C. P., Furman, M. I., Gurbel, P., Michelson, A. D., Peterson, E., Wiviott, S. Investigating the mechanisms of hyporesponse to antiplatelet approaches Clin Cardiol. 2008;31(3 Suppl 1):I21-7. Abstract

Gibson, C. M., Murphy, S. A., Pride, Y. B., Kirtane, A. J., Aroesty, J. M., Stein, E. B., Ciaglo, L. N., Southard, M. C., Sabatine, M. S., Cannon, C. P., Braunwald, E. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study Am Heart J. 2008;155(1):133-9.

Murphy, S. A., Antman, E. M., Wiviott, S. D., Weerakkody, G., Morocutti, G., Huber, K., Lopez-Sendon, J., McCabe, C. H., Braunwald, E. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial Eur Heart J. 2008;29(20):2473-9. Abstract

Wiviott, S. D., Braunwald, E., Angiolillo, D. J., Meisel, S., Dalby, A. J., Verheugt, F. W., Goodman, S. G., Corbalan, R., Purdy, D. A., Murphy, S. A., McCabe, C. H., Antman, E. M. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38 Circulation. 2008;118(16):1626-36. Abstract

Wiviott, S. D., Braunwald, E., Murphy, S. A., Antman, E. M. A perspective on the efficacy and safety of intensive antiplatelet therapy in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38 Am J Cardiol. 2008;101(9):1367-70.

Desai, N. R., Mega, J. L., Jiang, S., Cannon, C. P., Sabatine, M. S. Interaction between cigarette smoking and clinical benefit of clopidogrel Journal of the American College of Cardiology. 2009;53(15):1273-8. Abstract

Gibson, C. M., Pride, Y. B., Buros, J. L., Ciaglo, L. N., Morrow, D. A., Scirica, B. M., Stone, P. H. Timing and duration of myocardial ischemia on Holter monitoring following percutaneous coronary intervention and their association with clinical outcomes (a PROTECT-TIMI 30 Substudy Analysis) Am J Cardiol. 2009;104(1):36-40.

Giugliano, R. P., White, J. A., Bode, C., Armstrong, P. W., Montalescot, G., Lewis, B. S., van 't Hof, A., Berdan, L. G., Lee, K. L., Strony, J. T., Hildemann, S., Veltri, E., Van de Werf, F., Braunwald, E., Harrington, R. A., Califf, R. M., Newby, L. K. Early versus delayed, provisional eptifibatide in acute coronary syndromes N Engl J Med. 2009;360(21):2176-90. Abstract

Husted, S., Harrington, R. A., Cannon, C. P., Storey, R. F., Mitchell, P., Emanuelsson, H. Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial Int J Clin Pract. 2009;63(4):667-70. Abstract

Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W. L., Braunwald, E., Sabatine, M. S. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation. 2009;119(19):2553-60. Abstract

Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E., Sabatine, M. S. Cytochrome p-450 polymorphisms and response to clopidogrel New England journal of medicine. 2009;360(4):354-62. Abstract

Michelson, A. D., Frelinger, A. L., 3rd, Braunwald, E., Downey, W. E., Angiolillo, D. J., Xenopoulos, N. P., Jakubowski, J. A., Li, Y., Murphy, S. A., Qin, J., McCabe, C. H., Antman, E. M., Wiviott, S. D. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial European heart journal. 2009;30(14):1753-63. Abstract

Montalescot, G., Wiviott, S. D., Braunwald, E., Murphy, S. A., Gibson, C. M., McCabe, C. H., Antman, E. M. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet. 2009;373(9665):723-31. Abstract

Morrow DA, Scirica BM, Fox KA, Berman G, Strony J, Veltri E, Bonaca MP, Fish P, McCabe CH, Braunwald E. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2˚P)-TIMI 50 trial. Am Heart J. 2009;158:335-341 e3. Abstract

Morrow, D. A., Wiviott, S. D., White, H. D., Nicolau, J. C., Bramucci, E., Murphy, S. A., Bonaca, M. P., Ruff, C. T., Scirica, B. M., McCabe, C. H., Antman, E. M., Braunwald, E. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the universal definition of myocardial infarction Circulation. 2009;119(21):2758-64. Abstract

O'Donoghue, M. L., Braunwald, E., Antman, E. M., Murphy, S. A., Bates, E. R., Rozenman, Y., Michelson, A. D., Hautvast, R. W., Ver Lee, P. N., Close, S. L., Shen, L., Mega, J. L., Sabatine, M. S., Wiviott, S. D. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials Lancet. 2009;374(9694):989-97. Abstract

O'Donoghue, M., Antman, E. M., Braunwald, E., Murphy, S. A., Steg, P. G., Finkelstein, A., Penny, W. F., Fridrich, V., McCabe, C. H., Sabatine, M. S., Wiviott, S. D. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis Journal of the American College of Cardiology. 2009;54(8):678-85. Abstract

Pride, Y. B., Wiviott, S. D., Buros, J. L., Zorkun, C., Tariq, M. U., Antman, E. M., Braunwald, E., Gibson, C. M. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy American heart journal. 2009;158(3):e21-6. Abstract

Storey, R. F., Melissa Thornton, S., Lawrance, R., Husted, S., Wickens, M., Emanuelsson, H., Cannon, C. P., Heptinstall, S., Armstrong, M. Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3 Platelets. 2009;20(5):341-8. Abstract

Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., Mahaffey, K. W., Scirica, B. M., Skene, A., Steg, P. G., Storey, R. F., Harrington, R. A., Plato Investigators, Freij, A., Thorsen, M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med. 2009;361(11):1045-57. Abstract

Wrishko, R. E., Ernest, C. S., 2nd, Small, D. S., Li, Y. G., Weerakkody, G. J., Riesmeyer, J. R., Macias, W. L., Rohatagi, S., Salazar, D. E., Antman, E. M., Wiviott, S. D., Braunwald, E., Ni, L. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38 Journal of clinical pharmacology. 2009;49(8):984-98. Abstract

Bhatt, D. L., Cryer, B. L., Contant, C. F., Cohen, M., Lanas, A., Schnitzer, T. J., Shook, T. L., Lapuerta, P., Goldsmith, M. A., Laine, L., Scirica, B. M., Murphy, S. A., Cannon, C. P., Cogent Investigators Clopidogrel with or without omeprazole in coronary artery disease N Engl J Med. 2010;363(20):1909-17. Abstract

Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, Husted S, Katus H, Keltai M, Khurmi NS, Kontny F, Lewis BS, Steg PG, Storey RF, Wojdyla D, Wallentin L. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375:283-93. Abstract

Gibler, K. B., Huskamp, H. A., Sabatine, M. S., Murphy, S. A., Cohen, D. J., Cannon, C. P. Cost-effectiveness analysis of short-term clopidogrel therapy for ST elevation myocardial infarction Crit Pathw Cardiol. 2010;9(1):14-8. Abstract

Husted, S., Storey, R. F., Harrington, R. A., Emanuelsson, H., Cannon, C. P. Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel Clin Cardiol. 2010;33(4):206-12. Abstract

James S, Angiolillo DJ, Cornel JH, Erlinge D, Husted S, Kontny F, Maya J, Nicolau JC, Spinar J, Storey RF, Stevens SR, Wallentin L; PLATO Study Group. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. Euro Heart J. 2010;31:3006-3016. Abstract

Mahoney, E. M., Wang, K., Arnold, S. V., Proskorovsky, I., Wiviott, S., Antman, E., Braunwald, E., Cohen, D. J. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38 Circulation. 2010;121(1):71-9. Abstract

Maree, A. O., Vangjeli, C., Jneid, H., Ryan, J., Cox, D., Cannon, C. P., Shields, D. C., Fitzgerald, D. J. G-protein beta3 subunit polymorphism and bleeding in the orbofiban in patients with unstable coronary syndromes-thrombolysis in myocardial infarction 16 trial J Thromb Haemost. 2010;8(5):934-41. Abstract

Mauri, L., Kereiakes, D. J., Normand, S. L., Wiviott, S. D., Cohen, D. J., Holmes, D. R., Bangalore, S., Cutlip, D. E., Pencina, M., Massaro, J. M. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions Am Heart J. 2010;160(6):1035-41, 1041 e1. Abstract

Melloni, Chiara, James, Stefan K., White, Jennifer A., Giugliano, Robert P., Harrington, Robert A., Huber, Kurt, Armstrong, Paul W., Califf, Robert M., Van de Werf, Frans, Montalescot, Gilles, Newby, L. Kristin Safety and Efficacy of Adjusted-Dose Eptifibatide in Patients with Acute Coronary Syndromes and Reduced Renal Function J Am Coll Cardiol. 2010;55(10s1):A102.E957-A102.E957.

Pride, Y. B., Tung, P., Mohanavelu, S., Zorkun, C., Wiviott, S. D., Antman, E. M., Giugliano, R., Braunwald, E., Gibson, C. M. Angiographic and clinical outcomes among patients with acute coronary syndromes presenting with isolated anterior ST-segment depression: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) substudy JACC Cardiovascular interventions. 2010;3(8):806-11. Abstract

Steg PG, James S, Harrington RA, Ardissino D, Becker RC, Cannon CP, Emanuelsson H, Finkelstein A, Husted S, Katus H, Kilhamn J, Olofsson S, Storey RF, Weaver WD, Wallentin L; PLATO Study Group. Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention A Platelet Inhibition and Patient Outcomes (PLATO) Trial Subgroup Analysis. Circulation. 2010;122:2131-2141. Abstract

Tanguay, Jean-François, Newby, L. Kristin, Hochman, Judith, Westerhout, Cynthia M., Califf, Robert M., Gibson, C. Michael, Giugliano, Robert P., Harrington, Robert A., Van de Werf, Frans, Armstrong, Paul W. SEX DIFFERENCES IN HIGH-RISK ACUTE CORONARY SYNDROMES: INSIGHTS FROM EARLY-ACS J Am Coll Cardiol. 2010;55(10s1):A120.E1122-A120.E1122.

Wang, Tracy, White, Jennifer A., Giugliano, Robert P., Tricoci, Pierluigi, Harrington, Robert A., Montalescot, Gilles, Zeymer, Uwe, Van de Werf, Frans, Armstrong, Paul W., Braunwald, Eugene, Califf, Robert M., Newby, L. Kristin UPFRONT CLOPIDOGREL USE AND THE EFFICACY AND SAFETY OF EARLY EPTIFIBATIDE USE IN PATIENTS WITH ACUTE CORONARY SYNDROME: AN ANALYSIS FROM THE EARLY VERSUS DELAYED PROVISIONAL EPTIFIBATIDE IN ACUTE CORONARY SYNDROMES (EARLY ACS) TRIAL Journal of the American College of Cardiology. 2010;55(10, Supplement):A47.E451.

Wiviott, S. D., Antman, E. M., Braunwald, E. Mortality in the TRITON trial: update from the FDA prasugrel action package Am J Cardiol. 2010;106(2):293-4.

Wiviott, S. D., Antman, E. M., Braunwald, E. Prasugrel Circulation. 2010;122(4):394-403.

Wiviott, S. D., Mega, J. L. Another step on the road to tailored antiplatelet therapy J Am Coll Cardiol. 2010;56(20):1637-8.

Ahmed, S., Michael Gibson, C., Cannon, C. P., Murphy, S. A., Sabatine, M. S. Impact of reduced glomerular filtration rate on outcomes in patients with ST-segment elevation myocardial infarction undergoing fibrinolysis: a CLARITY-TIMI 28 analysis J Thromb Thrombolysis. 2011;31(4):493-500. Abstract

Bonaca, Marc P., Braunwald, Eugene, Murphy, Sabina A., Miller, Debra, Herrman, Jp R., Gottlieb, Shmuel, Menozzi, Alberto, McCabe, Carolyn H., Antman, Elliot M., Wiviott, Stephen W. LONG-TERM THIENOPYRIDINE THERAPY AND OUTCOMES IN PATIENTS WITH ACS TREATED WITH CORONARY STENTING: THE PRIMARY RESULTS OF THE TIMI-38 CORONARY STENT REGISTRY Journal of the American College of Cardiology. 2011;57(14, Supplement):E906.

Desai, N. R., Morrow, D. A., Murphy, S. A., Gerszten, R. E., Cannon, C. P., Sabatine, M. S. Evaluation of Multiple Biomarkers of Cardiomyocyte Stress or Injury to Predict Cardiovascular Death or CHF in STEMI: Findings from CLARITY-TIMI 28 Circulation. 2011;124(21):NA.

Don, C. W., Roe, M. T., Li, S., Fraulo, E., Pomerantsev, E., Palacios, I., Wiviott, S. D. Temporal trends and practice variations in clopidogrel loading doses in patients with non-ST-segment elevation myocardial infarction, from the National Cardiovascular Data Registry Am Heart J. 2011;161(4):689-97. Abstract

Frelinger, A. L., 3rd, Michelson, A. D., Wiviott, S. D., Trenk, D., Neumann, F. J., Miller, D. L., Jakubowski, J. A., Costigan, T. M., McCabe, C. H., Antman, E. M., Braunwald, E. Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. Results from PRINCIPLE-TIMI 44 Thrombosis and haemostasis. 2011;106(2):219-26. Abstract

Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ, Harrington RA, Horrow J, Husted S, James SK, Mahaffey KW, Nicolau JC, Scirica BM, Storey RF, Vintila M, Ycas J, Wallentin L. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011;57:672-84. Abstract

Hochholzer, W., Trenk, D., Mega, J. L., Morath, T., Stratz, C., Valina, C. M., O'Donoghue, M. L., Bernlochner, I., Contant, C. F., Guo, J., Sabatine, M. S., Schomig, A., Neumann, F. J., Kastrati, A., Wiviott, S. D., Sibbing, D. Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy Am Heart J. 2011;162(3):518-26 e5. Abstract

James SK, Roe MT, Cannon CP, Cornel JH, Horrow J, Husted S, Katus H, Morais J, Steg PG, Storey RF, Stevens S, Wallentin L, Harrington RA; PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. Brit Med J. 2011;342:d3527. Abstract

Kunadian, V., Zorkun, C., James, S., Wu, J. H., Muhammad, A., Storey, R., Steg, P. G., Katus, H., Emanuelsson, H., Horrow, J., Maya, J., Wallentin, L., Harrington, R., Gibson, C. M. ANGIOGRAPHIC OUTCOMES IN THE PLATELET INHIBITION AND PATIENT OUTCOMES (PLATO) TRIAL Journal of the American College of Cardiology. 2011;57(14):E946-E946.

Mega JL, Hochholzer W, Frelinger AL 3rd, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. J Am Med Assoc. 2011;306:2221-8. Abstract

Mega, J. L., Hochholzer, W., Frelinger, A. L., Kluk, M. J., Isserman, S., Rogers, W. J., Angiolillo, D. J., Kereiakes, D. J., Ruff, C. T., Berg, D. D., Cyr, J., Scirica, B. M., Grip, L., Mesa, R. A., Mattimore, J. F., Longtine, J. A., Michelson, A. D., Sabatine, M. S. ELEVATE-TIMI 56: Escalating Clopidogrel by Involving a Genetic Strategy-TIMI 56 Circulation. 2011;124(21):2371-2372. Abstract

Mega, Jessica L, Close, Sandra L, Wiviott, Stephen D, Man, Michael, Duvvuru, Suman, Walker, Joseph, Sundseth, Scott S, Macias, William L, Antman, Elliott M, Braunwald, Eugene, Sabatine, Marc S Abstract 11255: PON1 Q192R (rs662) Genetic Variant and Response to Clopidogrel and Prasugrel Circulation. 2011;124(21 Supplement):A11255.

Melloni, C., James, S. K., White, J. A., Giugliano, R. P., Harrington, R. A., Huber, K., Tricoci, P., Armstrong, P. W., Van de Werf, F., Montalescot, G., Califf, R. M., Newby, L. K., Early ACS Investigators Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function. Am Heart J. 2011;162(5):884-892. Abstract

Melloni, C., Roe, M. T., Chen, A. Y., Wang, T. Y., Wiviott, S. D., Ho, P. M., Peterson, E. D., Alexander, K. P. Use of early clopidogrel by reperfusion strategy among patients presenting with ST-segment elevation myocardial infarction Circ Cardiovasc Qual Outcomes. 2011;4(6):603-9. Abstract

O'Donoghue, M. L., Bhatt, D. L., Wiviott, S. D., Goodman, S. G., Fitzgerald, D. J., Angiolillo, D. J., Goto, S., Montalescot, G., Zeymer, U., Aylward, P. E., Guetta, V., Dudek, D., Ziecina, R., Contant, C. F., Flather, M. D., Lancelot-Acs Investigators Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial Circulation. 2011;123(17):1843-53. Abstract

Scirica BM, Cannon CP, Emanuelsson H, Michelson EL, Harrington RA, Husted S, James S, Katus H, Pais P, Raev D, Spinar J, Steg PG, Storey RF, Wallentin L; PLATO Investigators. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy. J Am Coll Cardiol. 2011;57:1908-16. Abstract

Toleva O, Westerhout CM, Senaratne M, Bode C, Lindroos M, Ardissino D, Sulimov VA, Montalescot G, Newby LK, Giugliano RP, Van de Werf F, Armstrong PW Association of Hub and Spoke Practice Patterns with Coronary Interventino and Outcomes in Non ST Elevation Acute Coronary Syndromes (NSTE ACS): Insights from the Early Glycoprotein IIb/IIIa Inhibition in NSTE ACS (EARLY-ACS) Trial J Am Coll Cardiol. 2011;57(14):74.

Waks, J. W., Sabatine, M. S., Cannon, C. P., Morrow, D. A., Gibson, C. M., Wiviott, S. D., Giugliano, R. P., Sloan, S., Braunwald, E., Scirica, B. M. Improved Risk Stratification in Patients with ST-Elevation Myocardial Infarction Treated with Fibrinolysis by Combining New Q-Waves on the Initial Electrocardiogram with ST-Segment Resolution-Observations from the CLARITY-TIMI 28 Trial Circulation. 2011;124(21):NA.

Wiviott, S. D., Desai, N., Murphy, S. A., Musumeci, G., Ragosta, M., Antman, E. M., Braunwald, E. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies Am J Cardiol. 2011;108(7):905-11. Abstract

Wiviott, S. D., Hochholzer, W. On-clopidogrel platelet reactivity: a target in sight? J Am Coll Cardiol. 2011;58(19):1955-7.

Bohula May, Erin A, Bonaca, Marc P, Scirica, Benjamin M, Morais, Joao, Nieminen, Markku, Murphy, Sabina A, Braunwald, Eugene, Morrow, David A Abstract 19221: Rates of Arterial Revascularization in Patients Treated with Vorapaxar vs. Placebo in the TRA 2{degrees}P-TIMI 50 Trial Circulation. 2012;126(21 Supplement):A19221.

Bonaca, Marc P, Scirica, Benjamin M, Braunwald, Eugene, Wiviott, Stephen D, Goto, Shinya, Nilsen, Dennis, Bonarjee, Vernon, Murphy, Sabina A, Morrow, David A Abstract 19144: New Ischemic Stroke and Outcomes with Vorapaxar vs. Placebo: Results from TRA 2{degrees}P-TIMI 50 Trial Circulation. 2012;126(21 Supplement):A19144.

Hall, Hurst M, Enriquez, Jonathan R, de Lemos, James A, Desai, Nihar, Peng, S. Andrew, Alexander, Karen P, Roe, Matthew T, McGuire, Darren K, Wiviott, Stephen D, Das, Sandeep R Abstract 12693: Patterns of Discharge Aspirin Dosing in 213,344 U.S. Patients after Acute Myocardial Infarction: Results from the NCDR Circulation. 2012;126(21 Supplement):A12693.

Husted S, James S, Becker RC, Horrow J, Katus H, Storey RF, Cannon CP, Heras M, Lopes RD, Morais J, Mahaffey KW, Bach RG, Wojdyla D, Wallentin L; PLATO study group. Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial. Circ Cardiovasc Qual Outcomes. 2012;5:680-688. Abstract

James SK, Storey RF, Khurmi NS, Husted S, Keltai M, Mahaffey KW, Maya J, Morais J, Lopes RD, Nicolau JC, Pais P, Raev D, Lopez-Sendon JL, Stevens SR, Becker RC; PLATO Study Group. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack. Circulation. 2012;125:2914-2921. Abstract

Lopes, R. D., White, J. A., Tricoci, P., White, H. D., Armstrong, P. W., Braunwald, E., Giugliano, R. P., Harrington, R. A., Lewis, B. S., Brogan, G. X., Jr., Gibson, C. M., Califf, R. M., Newby, L. K. Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: Insights from the EARLY ACS trial International journal of cardiology. 2012;NA(NA):NA. Abstract

Maddox, T. M., Ho, P. M., Tsai, T. T., Wang, T. Y., Li, S., Peng, S. A., Wiviott, S. D., Masoudi, F. A., Rumsfeld, J. S. Clopidogrel use and hospital quality in medically managed patients with non-ST-segment-elevation myocardial infarction Circ Cardiovasc Qual Outcomes. 2012;5(4):523-31. Abstract

Morrow DA, Braunwald E, Bonaca MP, Ameriso SF, Dalby AJ, Fish MP, Fox KA, Lipka LJ, Liu X, Nicolau JC, Ophuis AJ, Paolasso E, Scirica BM, Spinar J, Theroux P, Wiviott SD, Strony J, Murphy, SA. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366:1404-13. Abstract

Moukarbel, G. V., Bhatt, D. L. Antiplatelet Therapy and Proton Pump Inhibition Clinician Update Circulation. 2012;125(2):375-380.

O'Donoghue, M. L., Bhatt, D. L., Flather, M. D., Goto, S., Angiolillo, D. J., Goodman, S. G., Zeymer, U., Aylward, P. E., Montalescot, G., Ziecina, R., Kobayashi, H., Ren, F., Wiviott, S. D. Atopaxar and its effects on markers of platelet activation and inflammation: results from the LANCELOT CAD program J Thromb Thrombolysis. 2012;34(1):36-43. Abstract

Piccini, J. P., White, J. A., Mehta, R. H., Lokhnygina, Y., Al-Khatib, S. M., Tricoci, P., Pollack, C. V., Jr., Montalescot, G., Van de Werf, F., Gibson, C. M., Giugliano, R. P., Califf, R. M., Harrington, R. A., Newby, L. K. Sustained ventricular tachycardia and ventricular fibrillation complicating non-ST-segment-elevation acute coronary syndromes Circulation. 2012;126(1):41-9. Abstract

Rasoul S, van't Hof A, Clare R, Atar D, James S, Tanguay J, Betriu A, Brogan G, Giugliano R, Newby LK Routine Early Eptifibatide, Infarct Size and Outcomes in Non-ST segment Elevation Acute Coronary Syndrome Patients with Elevated Troponins on Admission J Am Coll Cardiol. 2012;59(13):A121.

Roe, M. T., Armstrong, P. W., Fox, K. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., Ardissino, D., Nicolau, J. C., Boden, W. E., Gurbel, P. A., Ruzyllo, W., Dalby, A. J., McGuire, D. K., Leiva-Pons, J. L., Parkhomenko, A., Gottlieb, S., Topacio, G. O., Hamm, C., Pavlides, G., Goudev, A. R., Oto, A., Tseng, C. D., Merkely, B., Gasparovic, V., Corbalan, R., Cinteza, M., McLendon, R. C., Winters, K. J., Brown, E. B., Lokhnygina, Y., Aylward, P. E., Huber, K., Hochman, J. S., Ohman, E. M., Trilogy Acs Investigators Prasugrel versus clopidogrel for acute coronary syndromes without revascularization N Engl J Med. 2012;367(14):1297-309. Abstract

Ruff, C. T., Giugliano, R. P., Antman, E. M., Murphy, S. A., Lotan, C., Heuer, H., Merkely, B., Baracioli, L., Schersten, F., Seabro-Gomes, R., Braunwald, E., Wiviott, S. D. Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world Int J Cardiol. 2012;155(3):424-9. Abstract

Sarma, Amy, Wiviott, Stephen D, Antman, Elliott, Mega, Jessica L, Murphy, Sabina A, Hoffman, Elaine, Sabatine, Marc S, O'Donoghue, Michelle L Abstract 17455: Pharmacodynamic Response to Clopidogrel in Men versus Women: Insights from the PRINCIPLE-TIMI 44 Trial Circulation. 2012;126(21 Supplement):A17455.

Scirica BM, Bonaca MP, Braunwald E, De Ferrari GM, Isaza D, Lewis BS, Mehrhof F, Merlini PA, Murphy SA, Sabatine MS, Tendera M, Van de Werf F, Wilcox R, Morrow DA. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2˚P-TIMI 50 trial Lancet. 2012;380:1317-24. Abstract

Scirica, Benjamin M, Bonaca, Marc P, Braunwald, Eugene, Betriu, Amadeo, Moliterno, David J, Corbalan, Ramon, Murphy, Sabina A, Morrow, David A Abstract 14508: Vorapaxar for Secondary Prevention after Myocardial Infarction According to Aspirin Dose - Insights from the TRA2{degrees}P-TIMI 50 Trial Circulation. 2012;126(21 Supplement):A14508.

Scirica, Benjamin M, Bonaca, Marc P, Braunwald, Eugene, Diehm, Curt H, Hankey, Graeme J, Moliterno, David J, Murphy, Sabina A, Morrow, David A Abstract 14419: Natural History of Atherothrombotic Events According to the Primary Diseased Vascular Bed - Insights from the TRA2P-TIMI 50 Trial Circulation. 2012;126(21 Supplement):A14419.

Steen, Dylan L, Cannon, Christopher P, Lele, Suhas, Rajapurkar, Mohan, Mukhopadhyay, Banibrata, Scirica, Benjamin M, Morrow, David A Abstract 18754: Prognostic Evaluation of Catalytic Iron in Patients with Acute Coronary Syndromes: Observations from OPUS-TIMI 16 Circulation. 2012;126(21 Supplement):A18754.

Agrawal, K., Bhatt, D. L. Antiplatelet therapy: Does prasugrel or ticagrelor suffice in patients with STEMI? Nat Rev Cardiol. 2013;10(3):121-2.

Bagai, A., White, J. A., Lokhnygina, Y., Giugliano, R. P., Van de Werf, F., Montalescot, G., Armstrong, P. W., Tricoci, P., Gibson, C. M., Califf, R. M., Harrington, R. A., Newby, L. K. Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: An analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial Am Heart J. 2013;166(3):466-473 e1. Abstract

Bansilal S, Bonaca MP, Sabatine MS. Ticagrelor for acute coronary syndromes. Expert Rev Cardiovasc Ther. 2013;11:1473-84. Abstract

Bansilal, S., Wiviott, S., Becker, R., Harrington, R., Himmelmann, A., Neely, B., Husted, S., Storey, R., Steg, P., Katus, H., James, S., Wallentin, L., Cannon, C., Timi Study Group The Efficacy and Safety of Ticagrelor as Compared to Clopidogrel, with and without a Glycoprotein iib/iiia Inhibitor in Patients with Acute Coronary Syndromes Undergoin Percutaneous Intervention: A PLATO (Study of Platelet Inhibition and Patient Outcomes) Analysis Journal of the American College of Cardiology. 2013;61(10):A460.

Bhatt, D. L., Stone, G. W., Mahaffey, K. W., Gibson, C. M., Steg, P. G., Hamm, C. W., Price, M. J., Leonardi, S., Gallup, D., Bramucci, E., Radke, P. W., Widimsky, P., Tousek, F., Tauth, J., Spriggs, D., McLaurin, B. T., Angiolillo, D. J., Genereux, P., Liu, T., Prats, J., Todd, M., Skerjanec, S., White, H. D., Harrington, R. A., Champion Phoenix Investigators Effect of platelet inhibition with cangrelor during PCI on ischemic events N Engl J Med. 2013;368(14):1303-13. Abstract

Bohula May, E. A., Scirica, B., Bonaca, M., Murphy, S., Braunwald, E. B., Morrow, D., Brigham and Women's Hospital Prognostic Value of High-Sensitivity CRP for Cardiovascular Outcomes in TRA 2P - TIMI 50 Journal of the American College of Cardiology. 2013;61(10):A287.

Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, Lamp JM, Murphy SA, Braunwald E, Morrow DA Vorapaxar in Patients With Peripheral Artery Disease: Results From TRA 2˚P-TIMI 50 Circulation. 2013;127:1522-9. Abstract

Bonaca, M., Creager, M. A., Olin, J., Scirica, B., Bohula May, E. A., Murphy, S., Braunwald, E. B., Morrow, D., Timi Study Group Vorapaxar Reduces Peripheral revascularization Regardless of the Number of Diseased Territories: Insights from the TRA 2P - TIMI 50 Trial Journal of the American College of Cardiology. 2013;61(10):A504.

Bonaca, Marc P, Scirica, Benjamin M, Braunwald, Eugene, Wiviott, Stephen D, Murphy, Sabina A, Morrow, David A Abstract 18928: Vorapaxar Reduces Coronary Stent Thrombosis: Results From the TRA2P-TIMI 50 Trial Circulation. 2013;128(22 Supplement):A18928.

Carreras, Edward T, Hochholzer, Willibald, Frelinger, Andrew L, Hoffman, Elaine B, O'Donoghue, Michelle L, Wiviott, Stephen D, Angiolillo, Dominick J, Michelson, Alan D, Sabatine, Marc S, Mega, Jessica L Abstract 12325: Diabetes Mellitus, CYP2C19 Genotype, and Pharmacodynamic Response to Clopidogrel Dosing: Insights From the ELEVATE-TIMI 56 Trial Circulation. 2013;128(22 Supplement):A12325.

Cavender, Matthew A, Scirica, Benjamin, Bonaca, Marc P, Morais, Joao, Oude Ophius, Ton, Dalby, Tony, Murphy, Sabina, Braunwald, Eugene, Morrow, David Abstract 10398: Vorapaxar in Patients With Diabetes and Prior MI: Findings From the TRA 2P - TIMI 50 Trial Circulation. 2013;128(22 Supplement):A10398.

De Luca, G., Van't Hof, A. W., Huber, K., Gibson, C. M., Bellandi, F., Arntz, H. R., Maioli, M., Noc, M., Zorman, S., Zeymer, U., Gabriel, H. M., Emre, A., Cutlip, D., Rakowski, T., Gyongyosi, M., Dudek, D., Egypt cooperation Impact of Hypertension on Distal Embolization, Myocardial Perfusion, and Mortality in Patients With ST Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty Am J Cardiol. 2013;112(8):1083-1086. Abstract

Desai, N. Variability in Response: Patterns in Prescribming Antiplatelet Therapy after CYP2C19 Genotyping among Patients with ACS and PCI Journal of the American College of Cardiology. 2013;61(10):A39.

Feres, F., Costa, R. A., Abizaid, A., Leon, M. B., Marin-Neto, J. A., Botelho, R. V., King, S. B., 3rd, Negoita, M., Liu, M., de Paula, J. E., Mangione, J. A., Meireles, G. X., Castello, H. J., Jr., Nicolela, E. L., Jr., Perin, M. A., Devito, F. S., Labrunie, A., Salvadori, D., Jr., Gusmao, M., Staico, R., Costa, J. R., Jr., de Castro, J. P., Abizaid, A. S., Bhatt, D. L., for the, Optimize Trial Investigators Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents: The OPTIMIZE Randomized Trial JAMA. 2013;NA(NA):NA. Abstract

Ferreiro, J. L., Bhatt, D. L., Ueno, M., Bauer, D., Angiolillo, D. J. Impact of Smoking on Long-Term Outcomes in Patients with Atherosclerotic Vascular Disease Treated with Aspirin or Clopidogrel: Insights from the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) Trial J Am Coll Cardiol. 2013;NA(NA):NA. Abstract

Frelinger, A. L., 3rd, Bhatt, D. L., Lee, R. D., Mulford, D. J., Wu, J., Nudurupati, S., Nigam, A., Lampa, M., Brooks, J. K., Barnard, M. R., Michelson, A. D. Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-Medications (Including Proton Pump Inhibitors), and Pre-Existent Variability in Platelet Function J Am Coll Cardiol. 2013;61(8):872-9. Abstract

Genereux, P., Stone, G. W., Harrington, R. A., Gibson, C. M., Steg, P. G., Brener, S. J., Angiolillo, D. J., Price, M. J., Prats, J., Lasalle, L., Liu, T., Todd, M., Skerjanec, S., Hamm, C. W., Mahaffey, K. W., White, H. D., Bhatt, D. L. Impact of Intra-procedural Stent Thrombosis during Percutaneous Coronary Intervention: Insights from the CHAMPION PHOENIX Trial J Am Coll Cardiol. 2013;NA(NA):NA. Abstract

James SK, Pieper KS, Cannon CP, Storey RF, Becker RC, Steg PG, Wallentin L, Harrington RA; PLATO study group. Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke. 2013;44:1477-9.

Kohli P, Wallentin L, Reyes E, Horrow J, Husted S, Angiolillo DJ, Ardissino D, Maurer G, Morais J, Nicolau JC, Oto A, Storey RF, James SK, Cannon CP. Reduction in First and Recurrent Cardiovascular Events With Ticagrelor Compared With Clopidogrel in the PLATO Study. Circulation. 2013;127:673-80. Abstract

Kohli, P., Udell, J. A., Murphy, S. A., Cannon, C. P., Antman, E. M., Braunwald, E., Wiviott, S. D. Discharge Aspirin Dose and Clinical Outcomes in Patients with Acute Coronary Syndromes treated with Prasugrel vs. Clopidogrel: An Analysis from the TRITON-TIMI 38 Study J Am Coll Cardiol. 2013;NA(NA):NA. Abstract

Kunadian V, James SK, Wojdyla DM, Zorkun C, Wu J, Storey RF, Steg PG, Katus H, Emanuelsson H, Horrow J, Maya J, Wallentin L, Harrington RA, Gibson CM. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). JACC Cardiovasc Interv. 2013;6:671-83. Abstract

Leonardi, S., Truffa, A. A., Neely, M. L., Tricoci, P., White, H. D., Gibson, C. M., Wilson, M., Stone, G. W., Harrington, R. A., Bhatt, D. L., Mahaffey, K. W. A novel approach to systematically implement the universal definition of myocardial infarction: insights from the CHAMPION PLATFORM trial Heart. 2013;99(17):1282-7. Abstract

Lopes, R. D., White, J. A., Tricoci, P., White, H. D., Armstrong, P. W., Braunwald, E., Giugliano, R. P., Harrington, R. A., Lewis, B. S., Brogan, G. X., Jr., Gibson, C. M., Califf, R. M., Newby, L. K. Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial Int J Cardiol. 2013;167(6):2580-7. Abstract

Magnani, Giulia, Morrow, David A, Scirica, Benjamin M, Sabatine, Marc S, Murphy, Sabina A, Bonaca, Marc P Abstract 18728: Patterns of Antiplatelet Use in Patients With Stable Atherosclerosis: Insights From the Tra 2{degrees}P-timi 50 Trial Circulation. 2013;128(22 Supplement):A18728.

Morrow DA, Alberts MJ, Mohr JP, Ameriso SF, Bonaca MP, Goto S, Hankey GJ, Murphy SA, Scirica BM, Braunwald E. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013;44:691-8. Abstract

Murphy, S., Bohula May, Erin A., Bonaca, M. P., Scirica, B., Braunwald, E. B., Morrow, D., Brigham and Women's Hospital Procedural Bleeding with Vorapaxar versus Placebo in TRA 2P - TIMI 50 Trial Journal of the American College of Cardiology. 2013;61(10):A30.

Reed, G. W. Influence of Smoking on the Antiplatelet Effect of Clopidogrel Differs According to Dosing Stragegy: Insights from the GRAVITAS Trial Journal of the American College of Cardiology. 2013;61(10):A475.

Reed, G. W., Cannon, C. P. Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting Clin Cardiol. 2013;NA(NA):NA. Abstract

Reed, Grant W, Guo, Jianping, Hoffman, Elaine B, Maree, Andrew O, Shekar, Prem, Aranki, Sary, Rosenfield, Kenneth, Cannon, Christopher P Abstract 10331: Aspirin Responsiveness Testing Predicts Bleeding During Coronary Artery Bypass Grafting: The Verify Pre-Op - TIMI 45 Study Circulation. 2013;128(22 Supplement):A10331.

Scott, S. A., Sangkuhl, K., Stein, C. M., Hulot, J. S., Mega, J. L., Roden, D. M., Klein, T. E., Sabatine, M. S., Johnson, J. A., Shuldiner, A. R. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy: 2013 Update Clin Pharmacol Ther. 2013;NA(NA):NA.

Steen, Dylan L, Umez-Eronini, Amarachi A, Hoffman, Elaine B, Antman, Elliott M, Wiviott, Stephen D Abstract 17544: Utilization of Intensive Lipid-Lowering Therapy After an Acute Coronary Syndrome: Insights From the Triton-TIMI 38 Trial Circulation. 2013;128(22 Supplement):A17544.

Steg, P. G., Bhatt, D. L., Hamm, C. W., Stone, G. W., Gibson, C. M., Mahaffey, K. W., Leonardi, S., Liu, T., Skerjanec, S., Day, J. R., Iwaoka, R. S., Stuckey, T. D., Gogia, H. S., Gruberg, L., French, W. J., White, H. D., Harrington, R. A. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data Lancet. 2013;NA(NA):NA. Abstract

Steg, P. G., Mehta, S. R., Pollack, C. V., Jr., Bode, C., Cohen, M., French, W. J., Hoekstra, J., Rao, S. V., Ruzyllo, W., Ruiz-Nodar, J. M., Sabate, M., Widimsky, P., Kiss, R. G., Navarro Estrada, J. L., Hod, H., Kerkar, P., Guneri, S., Sezer, M., Ruda, M., Nicolau, J. C., Cavallini, C., Ebrahim, I., Petrov, I., Kim, J. H., Jeong, M. H., Ramos Lopez, G. A., Laanmets, P., Kovar, F., Gaudin, C., Fanouillere, K. C., Minini, P., Hoffman, E. B., Moryusef, A., Wiviott, S. D., Sabatine, M. S., T. A. O. Investigators Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial JAMA. 2013;310(11):1145-55. Abstract

Storey RF, James SK, Siegbahn A, Varenhorst C, Held C, Ycas J, Husted SE, Cannon CP, Becker RC, Steg PG, Åsenblad N, Wallentin L. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets. 2013;25:517-25. Abstract

Tantry, U. S., Bonello, L., Aradi, D., Price, M. J., Jeong, Y. H., Angiolillo, D. J., Stone, G. W., Curzen, N., Geisler, T., Ten Berg, J., Kirtane, A., Siller-Matula, J., Mahla, E., Becker, R. C., Bhatt, D. L., Waksman, R., Rao, S. V., Alexopoulos, D., Marcucci, R., Reny, J. L., Trenk, D., Sibbing, D., Gurbel, P. A. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to ADP Associated with Ischemia and Bleeding J Am Coll Cardiol. 2013;NA(NA):NA. Abstract

Tricoci, P., Leonardi, S., White, J., White, H. D., Armstrong, P. W., Montalescot, G., Giugliano, R. P., Gibson, C. M., Van de Werf, F., Califf, R. M., Harrington, R. A., Braunwald, E., Mahaffey, K. W., Newby, L. K. Cardiac Troponin after Percutaneous Coronary Intervention and 1-Year Mortality in NSTE ACS Using Systematic Evaluation of Biomarker Trends J Am Coll Cardiol. 2013;NA(NA):NA. Abstract

Wallentin L, Lindholm D, Siegbahn A, Wernroth L, Becker RC, Cannon CP, Cornel JH, Himmelmann A, Giannitsis E, Harrington RA, Held C, Husted S, Katus HA, Mahaffey KW, Steg PG, Storey RF, James SK; PLATO study group. Biomarkers in Relation to the Effects of Ticagrelor Compared with Clopidogrel in Non-ST-Elevation Acute Coronary Syndrome Patients Managed with or without In-Hospital Revascularization: A Substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation. 2013;129:293-303. Abstract

Wiviott, S. D., White, H. D., Ohman, E. M., Fox, K. A., Armstrong, P. W., Prabhakaran, D., Hafley, G., Lokhnygina, Y., Boden, W. E., Hamm, C., Clemmensen, P., Nicolau, J. C., Menozzi, A., Ruzyllo, W., Widimsky, P., Oto, A., Leiva-Pons, J., Pavlides, G., Winters, K. J., Roe, M. T., Bhatt, D. L. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial Lancet. 2013;382(9892):605-13. Abstract

Bonaca MP, Bhatt DL, Braunwald E, Cohen M, Steg PG, Storey RF, Held P, Jensen EC, Sabatine MS Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. Am Heart J. 2014;167:437-444. Abstract

Bonaca, M. P., Murphy, S. A., Miller, D., Herrman, J. P., Gottlieb, S., Keltai, M., Menozzi, A., Nicolau, J. C., Widimsky, P., Antman, E. M., Wiviott, S. D. Patterns of Long-term Thienopyridine Therapy and Outcomes in Patients With Acute Coronary Syndrome Treated With Coronary Stenting: Observations From the TIMI-38 Coronary Stent Registry Clin Cardiol. 2014;NA(NA):NA. Abstract

Bui, An, Cannon, Christopher, Steg, Philippe, Storey, Robert, Husted, Steen, Ren, Fang, James, Stefan, Michelson, Eric, Himmelmann, Anders, Wallentin, Lars, Scirica, Benjamin RISK OF CARDIOVASCULAR DEATH AND NON-SUSTAINED VENTRICULAR TACHYCARDIA DETECTED 30-DAYS AFTER ACUTE CORONARY SYNDROME IN THE PLATO (PLATELET INHIBITION AND PATIENT OUTCOMES) TRIAL Journal of the American College of Cardiology. 2014;63(12, Supplement):A298.

Carreras, E. T., Mega, J. L. Dual antiplatelet therapy for heart disease Circulation. 2014;129(21):e506-8.

Feres, F., Costa, R. A., Bhatt, D. L. Dual antiplatelet therapy after stent implantation--reply JAMA. 2014;311(14):1446-7.

Kidd, Stephen, Bonaca, Marc, Scirica, Benjamin, Murphy, Sabina, Braunwald, Eugene, Morrow, David UNIVERSAL CLASSIFICATION SYSTEM TYPE OF INCIDENT MYOCARDIAL INFARCTION IN PATIENTS WITH STABLE ATHEROSCLEROSIS: OBSERVATIONS FROM TRA 2°P-TIMI 50 Journal of the American College of Cardiology. 2014;63(12, Supplement):A1568.

Kunadian, V., Giugliano, R. P., Newby, L. K., Zorkun, C., Guo, J., Bagai, A., Montalescot, G., Braunwald, E., Califf, R. M., Van de Werf, F., Armstrong, P. W., Harrington, R., Gibson, C. M. Angiographic Outcomes With Early Eptifibatide Therapy in Non-ST-Segment Elevation Acute Coronary Syndrome (from the EARLY ACS Trial) Am J Cardiol. 2014;113(8):1297-305. Abstract

Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya J, Husted S, Steg PG, Cornel JH, Storey RF, Stevens SR, Wallentin L, James SK. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J. 2014;35:2083-93. Abstract

Sherwood, M. W., Wiviott, S. D., Peng, S. A., Roe, M. T., Delemos, J., Peterson, E. D., Wang, T. Y. Early clopidogrel versus prasugrel use among contemporary STEMI and NSTEMI patients in the US: insights from the National Cardiovascular Data Registry J Am Heart Assoc. 2014;3(2):e000849. Abstract

Timur, A. A., Murugesan, G., Zhang, L., Barnard, J., Bhatt, D. L., Kottke-Marchant, K. Multi-parameter assessment of platelet inhibition and its stability during aspirin and clopidogrel therapy Thromb Res. 2014;NA(NA):NA. Abstract

Vardi, M., Debidda, M., Bhatt, D. L., Mauri, L., Cannon, C. P. Evolving antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: results from a survey among US cardiologists Clin Cardiol. 2014;37(2):103-7. Abstract